Cargando…
Precision cancer therapy is impacted by oncogene-dependent epigenome remodeling
The cancer genome provides the blueprint for identifying oncogenic mutations driving tumor growth and these mutant proteins and pathways are the targets for precision cancer therapies. However, many oncogenes are capable of reprogramming the landscape of active portion of the genome, commonly known...
Autores principales: | Liu, Feng, Mischel, Paul S., Cavenee, Webster K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5871882/ https://www.ncbi.nlm.nih.gov/pubmed/29872691 http://dx.doi.org/10.1038/s41698-017-0005-2 |
Ejemplares similares
-
Arsenic reverses glioblastoma resistance to mTOR-targeted therapies
por: Iwanami, Akio, et al.
Publicado: (2013) -
mTORC2 dictates Warburg effect and drug resistance
por: Masui, Kenta, et al.
Publicado: (2014) -
Protein Acetylation at the Interface of Genetics, Epigenetics and Environment in Cancer
por: Harachi, Mio, et al.
Publicado: (2021) -
Codependency of Metabolism and Epigenetics Drives Cancer Progression: A Review
por: Masui, Kenta, et al.
Publicado: (2020) -
The metabolomic landscape plays a critical role in glioma oncogenesis
por: Masui, Kenta, et al.
Publicado: (2022)